Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RAF inhibition and induction of cutaneous squamous cell carcinoma
Caroline Robert, Jean‐Philippe Arnault, Christine Mateus
Current Opinion in Oncology (2010) Vol. 23, Iss. 2, pp. 177-182
Closed Access | Times Cited: 118

Showing 1-25 of 118 citing articles:

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert, Bogusława Karaszewska, Jacob Schachter, et al.
New England Journal of Medicine (2014) Vol. 372, Iss. 1, pp. 30-39
Open Access | Times Cited: 2470
Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter, et al.
New England Journal of Medicine (2012) Vol. 366, Iss. 8, pp. 707-714
Open Access | Times Cited: 2125
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Libero Santarpia, Scott M. Lippman, Adel K. El‐Naggar
Expert Opinion on Therapeutic Targets (2012) Vol. 16, Iss. 1, pp. 103-119
Open Access | Times Cited: 934
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Niccolò Bolli, Hervé Avet‐Loiseau, David C. Wedge, et al.
Nature Communications (2014) Vol. 5, Iss. 1
Open Access | Times Cited: 821
Cutaneous melanoma
Alexander M.M. Eggermont, Alan Spatz, Caroline Robert
The Lancet (2013) Vol. 383, Iss. 9919, pp. 816-827
Closed Access | Times Cited: 504
Negative feedback regulation of the ERK1/2 MAPK pathway
David A. Lake, Sônia A. L. Corrêa, Jürgen Müller
Cellular and Molecular Life Sciences (2016) Vol. 73, Iss. 23, pp. 4397-4413
Open Access | Times Cited: 483
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Patrick A. Oberholzer, Damien Kee, Piotr Dziunycz, et al.
Journal of Clinical Oncology (2011) Vol. 30, Iss. 3, pp. 316-321
Open Access | Times Cited: 371
Raf kinases in cancer–roles and therapeutic opportunities
Gabriele D. Maurer, Bartosz Tarkowski, Manuela Baccarini
Oncogene (2011) Vol. 30, Iss. 32, pp. 3477-3488
Open Access | Times Cited: 283
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
Margaret K. Callahan, Raajit K. Rampal, James J. Harding, et al.
New England Journal of Medicine (2012) Vol. 367, Iss. 24, pp. 2316-2321
Open Access | Times Cited: 233
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia, Naveen Yarlagadda, Ramez Awad, et al.
OncoTargets and Therapy (2018) Vol. Volume 11, pp. 7095-7107
Open Access | Times Cited: 231
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Tim Eisen, Cora N. Sternberg, Caroline Robert, et al.
JNCI Journal of the National Cancer Institute (2012) Vol. 104, Iss. 2, pp. 93-113
Open Access | Times Cited: 202
Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAFV600EMutation
Kevin B. Kim, Maria E. Cabanillas, Alexander J. Lazar, et al.
Thyroid (2013) Vol. 23, Iss. 10, pp. 1277-1283
Open Access | Times Cited: 198
New drugs in melanoma: It’s a whole new world
Alexander M.M. Eggermont, Caroline Robert
European Journal of Cancer (2011) Vol. 47, Iss. 14, pp. 2150-2157
Closed Access | Times Cited: 183
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
Rachael Anforth, Tatiana Blumetti, Richard Kefford, et al.
British Journal of Dermatology (2012) Vol. 167, Iss. 5, pp. 1153-1160
Closed Access | Times Cited: 174
Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
Emily Y. Chu, Karolyn A. Wanat, Christopher J. Miller, et al.
Journal of the American Academy of Dermatology (2012) Vol. 67, Iss. 6, pp. 1265-1272
Open Access | Times Cited: 173
Clinicopathological relevance of BRAF mutations in human cancer
Sahar Pakneshan, Ali Salajegheh, Robert A. Smith, et al.
Pathology (2013) Vol. 45, Iss. 4, pp. 346-356
Closed Access | Times Cited: 152
Phosphorylation of BRAF by AMPK Impairs BRAF-KSR1 Association and Cell Proliferation
Che-Hung Shen, Ping Yuan, Rolando Pérez‐Lorenzo, et al.
Molecular Cell (2013) Vol. 52, Iss. 2, pp. 161-172
Open Access | Times Cited: 125
Epidemiology of skin cancer in the mature patient
Vivien Wai Yun Lai, William Cranwell, Rodney Sinclair
Clinics in Dermatology (2017) Vol. 36, Iss. 2, pp. 167-176
Closed Access | Times Cited: 125
Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1
J.-P. Arnault, Christine Mateus, Bernard Escudier, et al.
Clinical Cancer Research (2011) Vol. 18, Iss. 1, pp. 263-272
Open Access | Times Cited: 120
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
Sascha Dietrich, Andreas Pircher, Volker Endris, et al.
Blood (2016) Vol. 127, Iss. 23, pp. 2847-2855
Open Access | Times Cited: 116
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
Margaret K. Callahan, Gregg Masters, Christine A. Pratilas, et al.
Cancer Immunology Research (2013) Vol. 2, Iss. 1, pp. 70-79
Open Access | Times Cited: 114
ENDOCRINE TUMOURS: Approach to the patient with advanced differentiated thyroid cancer
M Schlumberger, Steven I. Sherman
European Journal of Endocrinology (2011) Vol. 166, Iss. 1, pp. 5-11
Open Access | Times Cited: 109
Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway
Victor Huang, Donna M. Hepper, Milan J. Anadkat, et al.
Archives of Dermatology (2012) Vol. 148, Iss. 5
Closed Access | Times Cited: 99
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management
Ioannis Manousaridis, Sofia Mavridou, Sergij Goerdt, et al.
Journal of the European Academy of Dermatology and Venereology (2012) Vol. 27, Iss. 1, pp. 11-18
Closed Access | Times Cited: 89
The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring
Aubrey A. Carhill, Maria E. Cabanillas, Camilo Jiménez, et al.
The Journal of Clinical Endocrinology & Metabolism (2012) Vol. 98, Iss. 1, pp. 31-42
Open Access | Times Cited: 88
Page 1 - Next Page

Scroll to top